RT Journal Article SR Electronic T1 Promising efficacy of following a third dose of mRNA SARS-CoV-2 vaccination in patients treated with anti-CD20 antibody who failed 2-dose vaccination JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.04.28.22274174 DO 10.1101/2022.04.28.22274174 A1 Yohei Funakoshi A1 Kimikazu Yakushijin A1 Goh Ohji A1 Wataru Hojo A1 Hironori Sakai A1 Marika Watanabe A1 Akihito Kitao A1 Yoshiharu Miyata A1 Yasuyuki Saito A1 Shinichiro Kawamoto A1 Katsuya Yamamoto A1 Mitsuhiro Ito A1 Taiji Koyama A1 Yoshinori Imamura A1 Naomi Kiyota A1 Hiroshi Matsuoka A1 Yasuko Mori A1 Hironobu Minami YR 2022 UL http://medrxiv.org/content/early/2022/05/01/2022.04.28.22274174.abstract AB Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for S1 protein after third vaccination in 22 patients treated with anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving seroconversion rate in patients treated with anti-CD20 antibody who failed standard two-dose vaccination.Competing Interest StatementKYak has received research grants and honoraria from Chugai Pharmaceutical. WH and HS are employed by Cellspect Co., Ltd. NK has received grants from Roche Phamaceuticals. HM has received research grants and honoraria from Chugai Pharmaceutical. The other authors declare no potential conflicts of interest.Funding StatementDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of MedicineAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Kobe University Hospital Ethics Committee (No. B2056714, 1481), and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent to participate.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.